Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 in type 2 diabetes with high HbA1c
NCT01785771Phase 3Terminated
- Sponsor
- Intarcia Therapeutics
- Start
- May 2013
- Primary completion
- Jan 2018
- Modality
- Peptides, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 3 trial of ITCA 650 in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Started May 2013; status: terminated.
02
Drugs
ITCA 650
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01785771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01785771.